[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"fasting\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:fasting":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,59,100,137,162,189,213,238,260,294,315,334,358,388,418,447,473,494,533],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":44,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100637347","phase-3-a-study-of-orforglipron-ly3502970-in-participants-with-type-2-diabetes-who-observe-ramadan-fasting-100637347",false,"NCT07613307","A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting","A Phase 3b, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Orforglipron in Adult Participants With Type 2 Diabetes Who Observe Ramadan Fasting (ACHIEVE-RAM)","ACHIEVE-RAM","Inclusion Criteria:\n\n* Have a clinical diagnosis of T2D based on the World Health Organization (WHO) classification or other locally applicable diagnostic standards.\n* Have an HbA1c value of at least 7.0% (53 millimoles per mole (mmol\u002Fmol)) to less than 9.5% (91 mmol\u002Fmol) at screening.\n* Intend to be compliant with the fast during the Ramadan period.\n* Have had stable body weight self-reported change of 5 kilograms (kg) or lower during the 90 days prior to screening.\n* Have body mass index (BMI) of 25 kilograms per meter square (kg\u002Fm2) or higher at screening.\n\nExclusion Criteria:\n\n* Have any form of diabetes other than T2D, including type 1 diabetes (T1D), gestational diabetes, latent autoimmune diabetes, maturity-onset diabetes of the young, and medication-induced diabetes\n* Have a family (first-degree relative) or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.\n* Have a history of chronic or acute pancreatitis any time prior to screening\n* Have evidence of a significant, uncontrolled endocrine abnormality, for example, thyrotoxic or adrenal crises, in the opinion of the investigator\n* Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years.\n* Have a history of cholecystectomy (surgically removed gallbladder)\n* Have New York Heart Association Functional Classification IV congestive heart-failure.","ALL","18 Years","65 Years",{"count":21,"type":22},130,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan. For each participant, the study will last up to 48 weeks with a minimum of 7 in clinic visits and 4 virtual visits.",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43],"Diabetes Mellitus, Type 2","Diabetes Melletus","Glucose Metabolism Disorders","Metabolic Disorders","Nutritional and Metabolic Diseases","Endocrine System Diseases","Feeding Behavior","Behavior","Fasting","Glucagon-Like Peptide-1 Receptor","Glucagon-Like Peptide Receptors","Receptors, G-Protein-Coupled","Receptors, Cell Surface","Membrane Proteins","Proteins","Receptors, Peptide",[45,36],"Ramadan","NOT_YET_RECRUITING","2026-06-18",{"date":49,"type":50},"2026-06-23","ACTUAL",{"date":52,"type":22},"2026-07",{"date":54,"type":22},"2027-05",{"name":56,"class":57},"Eli Lilly and Company","INDUSTRY",37,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":67,"targetDuration":4,"studyType":23,"phases":69,"briefSummary":71,"conditions":72,"keywords":76,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":5},"100573804","preoperative-fasting-vs-not-fasting-in-critically-ill-patients-100573804","NCT06751043","Preoperative Fasting vs. Not Fasting in Critically Ill Patients","FEEDS Trial - Fasting Preprocedurally in Enteral Nutrition: Evaluation of Divergent Approaches in Secure Airway","FEEDS","Inclusion Criteria:\n\n1. 1\\. Age ≥ 18\n2. Current admission to ICU\\*\n3. Secure airway\\*\\* with no plans for its removal prior to procedure\n4. Current non-trophic (\\> 10 mL\u002Fhr) tube (enteral) feeding\\*\\*\\* with no plans to discontinue prior to procedure for reasons other than preoperative fasting\n5. Planned eligible procedure (Examples are listed in Appendix C) with anesthesia care or nursing sedation. Eligible procedures are defined as non-emergent diagnostic or therapeutic interventions that:\n\n   * Do NOT have a well-established practice of preoperative fasting. (For example, bedside placement of a vascular catheter \\[arterial, central venous, peripheral venous\\] by the ICU team is NOT eligible for this trial since it has a widely established practice of no preoperative fasting and is not generally scheduled for a specific time.)\n   * Do NOT require fasting for preoperative gastrointestinal tract preparation\n   * Do NOT require removal\u002Freplacement of the endotracheal or tracheostomy tube\n   * Do NOT require prone or Trendelenburg (head-down) positioning.\n   * Typically require procedural sedation or anesthesia care.\n   * Generally, are scheduled for a specific time (although this time can change, or procedure may be cancelled).\n   * Are performed in the operating room, non-operating room procedural areas, or at the patient's bedside.\n\n     * All ICU types are eligible: surgical, medical, cardiac, neurological, trauma, mixed etc.\n\n       * Secure airway is defined as a cuffed endotracheal tube or a cuffed tracheostomy tube.\n\n         * Patients with all types of feeding tubes are eligible, regardless of tube insertion site (nasal, oral, surgically implanted) and tube tip location (pre- and post-pyloric) †As determined by the enrolling physician-investigator\n\nExclusion Criteria\n\n1. Inability to obtain informed consent\n2. Inability to enroll and randomize \\> 8 hours prior to planned procedure time\n3. Inability to deliver trial interventions\n4. Expected survival \\\u003C 48 hours as determined by the enrolling physician-investigator\n5. Critically ill burn patient\n6. Emergency procedure\n7. a. Gastrointestinal tract procedure that requires fasting based on surgical indications or b. airway\u002Flung procedure that requires removal of endotracheal or tracheostomy tube\n8. Plan for prone or Trendelenburg (head down) positioning during most of the procedure\n9. Major impairment of gastrointestinal motility or major structural disease of the gastrointestinal tract (e.g., severe gastroparesis, bowel obstruction, severe ileus, severely compromised lower esophageal sphincter, active gastrointestinal bleeding)\n10. Plan for postoperative extubation in the procedure area\n11. Prisoner\n12. Pregnant woman, woman of childbearing potential without a documented negative urine or serum pregnancy test during the current hospitalization, or woman who is breast feeding\n13. Refusal to enroll patient by treating physician\n14. Extracorporeal Membrane Oxygenation (ECMO) at the time of potential enrollment, except patients scheduled for ECMO decannulation as the study procedure and patients expected to be off of ECMO at the time of study procedure.\n15. Chronic mechanical ventilation at pre-admission level of care",{"count":68,"type":22},1072,[70],"NA","The goal of this clinical trial is to learn if fasting or not fasting before a procedure has an effect on recovery in those who are critically ill. The main questions it aims to answer for patients on a breathing machine who are receiving tube feeding are:\n\n* Does the risk of lung complications and death differ between those who are not fasting, which may have a higher chance of allowing tube feeding to enter the lungs, and fasting, which temporarily stops nutrition before a procedure?\n* Is there a difference in recovery times, hospital stays, infection rates, need for organ support, safety, and nutrition for those who either fast or do not fast before a procedure?\n* What is the relationship between nutrition and clinical outcomes?\n\nResearchers will compare not fasting and fasting to see if it has an effect on recovery.\n\nParticipants will:\n\n* Be assigned by chance (like a coin toss) to one of two groups. One group (fasting group) will have their tube feeding stopped at least 8 hours before their procedure. The other group (not fasting group) will have their tube feeding stopped right before their procedure.\n* Be monitored via medical record for amount of protein and calories received, and any complications related to fasting\u002Fnot fasting.\n\n  * Data from routine electronic medical records will be reviewed to determine how participants are doing 3 months after their procedure.\n\n'",[73,74,75,36],"Critical Illness","Surgical Procedure, Unspecified","Pulmonary Aspiration",[77,78,79,80,81,82,83,84,85,86,87,88],"pulmonary aspiration","enteral nutrition","tube feeding","preoperative fasting","perioperative medicine","surgery in critically ill","procedures in critically ill","nutrition in critical illness","perioperative safety","preoperative management","preoperative fasting in secure airway","anesthesia in critically ill","RECRUITING","2026-06-10",{"date":92,"type":50},"2026-06-12",{"date":94,"type":50},"2025-04-28",{"date":96,"type":22},"2028-05",{"name":98,"class":99},"Massachusetts General Hospital","OTHER",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":108,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":113,"conditions":114,"keywords":119,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100643224","mitophagy-and-mitochondrial-dna-dynamics-during-ramadan-dry-fasting-vs-168-time-restricted-feeding-100643224","NCT07638696","Mitophagy and Mitochondrial DNA Dynamics During Ramadan Dry Fasting vs 16:8 Time-Restricted Feeding","Mitophagic Flux and Mitochondrial DNA Dynamics During Circadian-Aligned Ramadan Dry Fasting Versus 16:8 Time-Restricted Feeding: A Four-Phase Translational Research Programme","MITO FAST","Inclusion Criteria:\n\n* Common Criteria (Both Arms):\n* Age 18-50 years\n* BMI 18.5-30.0 kg\u002Fm²\\[cite: 1\\]\n* Non-smoker for at least 12 months\\[cite: 1\\]\n* No chronic disease requiring regular prescription medication\\[cite: 1\\]\n* Stable sleep-wake schedule (self-reported sleep midpoint deviation less than 90 minutes)\\[cite: 1\\]\n* Willing and able to attend all five study visits at the specified times\\[cite: 1\\]\n\nArm A Specific (Ramadan Dry Fasting):\n\n\\- Documented religious commitment and intention to complete all 30 days of Ramadan 2027 fasting\\[cite: 1\\]\n\nArm B Specific (16:8 TRF Control):\n\n* Confirmed practice of 16:8 TRF (fasting window 16 hours or more per day) throughout the study period\\[cite: 1\\]\n* Not observing Ramadan dry fasting during the study period\\[cite: 1\\]\n\nExclusion Criteria:\n\n* Established type 1 or type 2 diabetes (HbA1c 6.5% or higher or pharmacological antidiabetic therapy)\\[cite: 1\\]\n* Severe gastrointestinal, cardiovascular, hepatic, or renal disease (eGFR less than 60 mL\u002Fmin\u002F1.73m²)\\[cite: 1\\]\n* Active cancer or chemotherapy within five years\\[cite: 1\\]\n* Use of metformin, statins, or exogenous antioxidant supplements (vitamins C, E, NAC, CoQ10) within 30 days of screening\\[cite: 1\\]\n* Pregnancy, lactation, or planned conception during the study period\\[cite: 1\\]\n* Participation in another clinical study within three months\\[cite: 1\\]\n* Inability to provide written informed consent in Arabic or English\\[cite: 1\\]",true,"50 Years",{"count":111,"type":22},120,"OBSERVATIONAL","This study investigates how different types of fasting affect cell health, specifically focusing on how mitochondria (the energy-producing parts of cells) are cleared and renewed. While standard intermittent fasting allows water intake, Ramadan dry fasting involves total restriction of both food and fluids from dawn to sunset.\n\nResearchers want to see if the combined effects of fluid restriction and natural daily body rhythms during Ramadan trigger a stronger cellular cleanup process (called mitophagy) compared to standard 16:8 water-permitted fasting. The study will look at how these fasting habits change blood markers related to mitochondrial DNA and metabolic health across a 30-day period. This research will help determine if dry fasting offers distinct biological benefits for cellular renewal.",[115,116,36,117,118],"Mitochondrial Degradation","Autophagy","Healthy Volunteers","Metabolic Adaptation",[120,121,122,123,124,125,126],"Ramadan fasting","Intermittent dry fasting","Time-restricted feeding","Mitochondrial DNA","Mitophagy","PBMC","PINK1-Parkin","2026-06-09",{"date":129,"type":50},"2026-06-11",{"date":131,"type":22},"2027-01-15",{"date":133,"type":22},"2027-04-30",{"name":135,"class":99},"Bahcesehir Cyprus University",1,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":108,"sex":17,"minAge":18,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":148,"conditions":149,"keywords":150,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":136},"100633478","the-meta-shift-study-how-metabolic-shift-shapes-human-immunometabolism---a-fasting-trial-100633478","NCT07527208","The Meta-SHIFT Study: How Metabolic Shift Shapes Human Immunometabolism - a Fasting Trial","Meta-SHIFT","Inclusion Criteria:\n\n* Apparently healthy\n* Age 18-40y at the time of recruitment\n* BMI ≥ 18.5 and ≤ 24.9 kg\u002Fm2\n* Willing to participate in all study activities during the 3-day intervention\n* Signed informed consent\n\nExclusion Criteria:\n\n* Diagnosed with any chronic medical condition that can interfere with the study outcome (e.g., cardiovascular disease, cancer, diabetes mellitus type 1 or 2, liver disease, pulmonary disease, renal disease, inflammatory bowel disease, thyroid disease, long COVID, PASC)\n* Bleeding disorder (e.g., Hemophilia A\u002FB, Von Willebrand Disease, or low platelets), current anemia or current use of blood thinners or anticoagulants (e.g. warfarin, heparin)\n* Any acute or chronic infection disease or fever in the past month\n* Antibiotic use in the past 2 months\n* Use of any prescribed medications (incl. GLP-1 agonists), except for contraceptives\n* Usage of recreational drugs in the last three months\n* Unstable body weight (weight gain or loss \\>5% of total BW in the past three months)\n* Following any restrictive diet within one month of starting the study (for example a ketogenic diet or weight loss diet)\n* Fasted for 16 hours or longer in the past week\n* History of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, or binge eating disorder)\n* Allergic to one or more components of the standardized meal and\u002For shake (i.e., milk, wheat, and soy)\n* Average alcohol intake that exceeds 1 consumption\u002Fday or 7 consumptions\u002Fweek over the past month\n* Tobacco smoker or regular use of nicotine products\n* Donated or intend to donate blood from 2 months before the study until the end of the study\n* Being pregnant or lactating\n* Participation in another biomedical study during this study","40 Years",{"count":146,"type":22},28,[70],"During fasting, the body shifts from using carbohydrates to relying more on fat as its main source of energy. This process is known as the 'metabolic shift'. Fat tissue helps supply this energy by breaking down stored fat into fatty acids, which are released into the bloodstream and transported to organs throughout the body. In addition to fatty acids, many other substances in the blood (such as metabolites) change during fasting to help maintain normal body function.\n\nImmune cells also circulate in the blood and play an important role in protecting the body against infections and diseases such as cancer. However, it is not yet well understood how the metabolic shift during fasting affects immune cell function. The purpose of this study is to investigate how 24 hours of fasting influences immune cell metabolism and function.",[36],[36,125,151,152],"Adipose tissue","Energy metabolism","2026-05-04",{"date":155,"type":50},"2026-05-07",{"date":157,"type":22},"2026-06-01",{"date":159,"type":22},"2026-12",{"name":161,"class":99},"Cornell University",{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":108,"sex":17,"minAge":169,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":23,"phases":173,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":136},"100342680","comparison-of-residual-gastric-volume-between-children-who-drink-different-clear-oral-fluid-volume-100342680","NCT03741777","Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume","Comparison of Residual Gastric Volume Between Children Who Drink Different Clear Oral Fluid Volume Before Undergoing Elective Esophago-gastro-duodenoscopy (EGD) Procedure","Inclusion Criteria:\n\n* ASA classification: I and II\n* 13-17 years\n* IPD cases or the first OPD case\n* Scheduled for elective EGD procedure.\n* All participants, families or guardians will be fluent in English.\n\nExclusion Criteria:\n\n* Emergent EGD procedures\n* Patients with active upper GI bleeding\n* Patients who received preoperative oral medication\n* Patients who are diagnosed as GERD, achalasia or suspected to have gastroparesis status such as uncontrolled diabetes or end stage kidney disease.","13 Years","17 Years",{"count":172,"type":22},288,[70],"According to the American Society of Anesthesiologists (ASA) fasting guideline for patients undergoing elective surgery, the 2-hour fasting period is suggested for clear oral fluid (including water, pulp-free juice and tea or coffee without milk). This guideline does not give any suggestions for proper volume of clear oral fluid intake.\n\nThis study is a prospective randomized control trials in children aged 13 through 17 years who are scheduled for an elective upper GI endoscopy procedure in the Gastroenteral Procedure Unit (GPU) at Boston Children's Hospital. The participants will be randomly assigned into one of four groups: Group 1 will consume 3 ml\u002Fkg of clear fluid by mouth at 2-hour period before surgical scheduled time, Group 2 will consume 5 ml\u002Fkg, Group 3 will consume 7 ml\u002Fkg, and Group 4 will consume 10 ml\u002Fkg. The investigators plan to recruit 72 patients in each group and 288 patients for the whole study. Research team will collect patient's demographic data, vital signs, information about their EGD procedure. Then actual volume of the stomach content and acidity will be measured from the content that is suctioned from patient's stomach during upper GI endoscopy procedure.\n\nThe investigators believe that the information from this study will help establish a comprehensive NPO guideline.",[36,176],"Gastric Emptying",[178,179],"NPO time","Gastric content","2026-04-21",{"date":182,"type":50},"2026-04-24",{"date":184,"type":50},"2024-02-29",{"date":186,"type":22},"2027-12",{"name":188,"class":99},"Boston Children's Hospital",{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":108,"sex":17,"minAge":18,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":198,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":136},"100623454","phase-1-the-food-effect-on-pharmacokinetics-of-fixed-dose-combination-of-gemigliptindapagliflozinmetformin-in-healthy-volunteers-100623454","NCT07396844","The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin\u002FDapagliflozin\u002FMetformin in Healthy Volunteers","A Single Dose, Randomized, Open-label, Two-way Crossover Food-effect Bioavailbility Study of Fixed Dose Combination of Gemigliptin\u002FDapagliflozin\u002FMetformin 50\u002F10\u002F1000 mg Sustained Release Tablets Under Fasting and Fed Conditions in Healthy Volunteers","Inclusion Criteria:\n\n1. Healthy Thai male and female subjects between the ages of 18 to 55 years.\n2. Body mass index between 18.5 to 30.0 kg\u002Fm2.\n3. Normal laboratory values, including vital signs and physical examination, for all parameters in clinical laboratory tests at screening.\n4. Non-pregnant woman and not currently breast feeding.\n5. Female subjects abstain from either hormonal method of contraception or hormone replacement therapy.\n6. Male subjects who are willing or able to use effective contraceptive.\n7. Have voluntarily given written informed consent by the subject prior to participating in this study.\n\nExclusion Criteria:\n\n1. History of allergic reaction or hypersensitivity to gemigliptin or dapagliflozin or metformin.\n2. History of evidence of clinically significant renal, hepatic, gastrointestinal, hematological, endocrine, pulmonary or respiratory, cardiovascular, neurologic, allergic disease, or any significant ongoing chronic medical illness.\n3. History of evidence of diabetic ketoacidosis.\n4. History of evidence of genital infections, urinary tract infections within 14 days prior to check-in.\n5. Have a eGFR (CKD-EPI) \\\u003C 60 mL\u002Fmin\u002F1.73 m2.\n6. History or evidence of alcoholism or harmful use of alcohol within 2 years prior to screening.\n7. Participated in other clinical trial within 90 days prior to check-in.","55 Years",{"count":146,"type":22},[199],"PHASE1","This is a single dose, randomized, open-label, two-way crossover study to investigate the food-effect bioavailability of the fixed-dose combination of Gemigliptin\u002FDapagliflozin\u002FMetformin 50\u002F10\u002F1000 mg in healthy volunteers under fasting and fed conditions.",[202,36,203],"Healthy","Fed","2026-04-08",{"date":206,"type":50},"2026-04-13",{"date":208,"type":22},"2026-07-01",{"date":210,"type":22},"2026-07-31",{"name":212,"class":57},"LG Chem",{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":108,"sex":17,"minAge":219,"maxAge":18,"enrollmentInfo":220,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":222,"conditions":223,"keywords":227,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":136},"100491093","gastric-assessment-of-pediatric-patients-undergoing-surgery-100491093","NCT05674643","Gastric Assessment of Pediatric Patients Undergoing Surgery","Inclusion Criteria:\n\n* Perioperative patients with ASA classification 1-2\n* Ages: 2 years- less than 18 years\n* Locations: Longwood and Waltham campuses of Boston Childrens Hospital\n\nExclusion Criteria:\n\n* History of gastrointestinal surgery\n* Gastrostomy\n* Known GI dysmotility (cohort 1 only)\n* Acetaminophen allergy (cohort 1 only)\n* Liver or renal dysfunction- pre-diagnosed or, if available, when serum biomarkers are 2 standard deviations above the highest value considered normal for age. (cohort 1 only)\n* Consumption of acetaminophen in the 4 hours prior (cohort 1 only)","2 Years",{"count":221,"type":22},60,"The goal of this pilot prospective cohort study is to examine the reproducibility of gastric volume and emptying as measured by gastric ultrasound and its correlation to a gold-standard test for gastric emptying in the perioperative period in pediatric patients. The main questions it aims to answer are:\n\n* What is the reliability (inter-rater variability between expert and novice assessors, and intra-rater variability) of a) the gastric antral cross-sectional area (CSA) and b) gastric volume using the Perlas US qualitative grading assessment, measured by using an ultrasound device in pediatric patients undergoing general anesthesia for elective surgery?\n* What is the correlation between ultrasound assessment of gastric emptying by the antral-CSA and gastric emptying determined by the acetaminophen absorption test (AAT), the gold standard?\n\nThe study will include two cohorts. Cohort assignment will be based on age and anesthesia induction plan. Subjects \\>7yrs of age and expected to get an IV induction will be assigned to Cohort #1. Subjects \\\u003C7yrs of age and not expected to get an IV induction will be assigned to Cohort #2.\n\n* Cohort 1 will include abdominal ultrasound for gastric assessment AND the acetaminophen absorption test which includes administering enteral acetaminophen (tylenol) with 6 oz of water and drawing of blood samples through a peripheral intravenous line.\n* Cohort 2 will include subjects for whom a peripheral intravenous line placement is not part of routine pre-operative care. Procedures for Cohort 2 will include abdominal ultrasound only in the pre-op area (no tylenol). This cohort is included to examine the reliability of measurements across age groups.",[36,224,225,226],"Delayed Gastric Emptying","Aspiration Pneumonia","Respiratory Aspiration of Gastric Content",[228,229],"gastric ultrasound","pre-operative fasting","2026-03-27",{"date":232,"type":50},"2026-04-02",{"date":234,"type":50},"2023-02-01",{"date":236,"type":22},"2028-12-31",{"name":188,"class":99},{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":244,"targetDuration":4,"studyType":23,"phases":246,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":136},"100502249","effect-of-fasting-on-patient-outcomes-after-wide-awake-local-anesthesia-only-no-tourniquet-walant-procedures-100502249","NCT05819801","Effect of Fasting on Patient Outcomes After Wide-Awake, Local Anesthesia-only, No Tourniquet (WALANT) Procedures","Inclusion Criteria:\n\n* Patients undergoing wide-awake, local anesthetic-only, no-tourniquet (WALANT) procedures with the lead researcher.\n\nExclusion Criteria:\n\n* Patients with insulin-dependent diabetes or allergy to local anesthesia, \\\u003C 18 years of age, patients unable to follow up.",{"count":245,"type":22},134,[70],"The purpose of this study is to determine whether eating solid food prior to undergoing a wide awake local-only no tourniquet (WALANT) procedure reduces anxiety in patients or has any effect on outcomes. Patients will be split randomly into two groups and told whether to eat or fast before their procedure. We will then compare levels of anxiety and nausea on the day of the procedure as well as satisfaction with the procedure and other outcome measures at follow-up visits. Our hypothesis is that patients who are instructed to eat before their WALANT procedure will have less anxiety, nausea, and overall higher satisfaction compared to those who are instructed to fast prior to their procedure.",[249,250,36],"Surgery","Anesthesia, Local","2026-03-11",{"date":253,"type":50},"2026-03-12",{"date":255,"type":50},"2024-02-22",{"date":257,"type":22},"2026-09",{"name":259,"class":99},"University of California, Irvine",{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":23,"phases":270,"briefSummary":271,"conditions":272,"keywords":277,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":293},"100555352","non-inferiority-of-continuing-oral-intake-versus-fasting-in-patients-with-acute-respiratory-failure-100555352","NCT06510972","Non-inferiority of Continuing Oral Intake Versus Fasting in Patients With Acute Respiratory Failure","Continuation of Oral Intake Compared With Fasting in Patients With Acute Respiratory Failure Before Intubation : a Non-inferiority Randomized Clinical Trial","JEUN-TUBE","Inclusion Criteria:\n\n* Male or female ≥ 18 years old\n* Participant affiliated to a social security scheme\n* Express oral consent of the participant, or failing that of the trusted support person, or failing that of the next of kin\n* Patient hospitalised in an intensive care unit or in a continuous surveillance unit or in an intensive care unit for less than 24 hours.\n* Criteria for acute hypoxaemic respiratory failure defined as.\n\n  * Respiratory rate \\> 25 cpm or indifferent if SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2) infection occurred ≥ 1 time since admission.\n  * PaO2\u002FFiO2 \\\u003C 200 mmHg or equivalent SpO2 (oxygen saturation)\u002FFiO2 (fraction of inspired oxygen) i.e. \\\u003C 235 (measured under at least 10 L\u002Fmin high concentration mask)\n\nExclusion Criteria:\n\n* Patient with criteria for immediate intubation:\n\n  * Persistent or worsening respiratory failure (respiratory rate \\> 40\u002Fmin, respiratory failure on physical examination, respiratory acidosis with pH (hydrogen potential ) \\\u003C 7.25, copious tracheal secretions, hypoxia with SpO2 \\\u003C 90% despite FiO2 \\> 80% for more than 5 minutes without technical dysfunction).\n  * Major haemodynamic failure (need for increasing vasopressor support with instability and hypoperfusion).\n  * Neurological failure (Glasgow score \\\u003C 8).\n  * Cardiac or respiratory arrest\n* Chronic lung disease: chronic obstructive pulmonary disease (GOLD grade 3 or 4: Global Initiative for Chronic Obstructive Lung Disease) or other chronic lung disease requiring long-term oxygen or ventilation (this does not include a patient undergoing continuous positive nocturnal pressure for sleep apnoea syndrome).\n* Contraindications to oral nutrition: known previous swallowing problems or inability to swallow, digestive sutures, admission for inhalation pneumonia, exclusive parenteral nutrition, etc.\n* Patients with a nasogastric or orogastric tube, a jejunostomy or a feeding ileostomy\n* Patient already on invasive mechanical ventilation on admission\n* Limitation of therapies including a decision not to intubate\n* Incapacitated adult (guardianship or curators)\n* Pregnant, parturient or breast-feeding women\n* Tracheostomised patient\n* Patient already included for the first time in this study",{"count":269,"type":22},754,[70],"Fasting in intensive care is mainly studied in mechanically ventilated patients or those in the weaning phase. Recent research challenge the common assumption of fasting and suggests that continuing enteral nutrition before extubation may be beneficial. Fasting is also practiced before procedures (e.g., tracheostomy, endoscopy) or surgeries, based on anesthetic guidelines. Yet, no data address fasting in non-intubated ICU patients with acute respiratory failure, despite frequent caloric deficits and inadequate nutritional intake.\n\nAspiration risk often justifies fasting, but studies indicate that swallowing reflexes remain intact in patients receiving high-flow nasal oxygen or non-invasive ventilation. Moreover, although intubation carries a 2-5.9% aspiration risk, rapid sequence induction mitigates this, questioning the necessity of preventive fasting. Despite its prevalence, this practice lacks scientific validation and guideline support.\n\nPatient discomfort is also significant. Hunger and thirst are major sources of distress, and evidence from anesthesiology suggests that allowing fluid intake pre-anesthesia reduces discomfort. Extrapolating these findings to ICU patients could improve well-being.\n\nIn conclusion, fasting in ICU patients may contribute to discomfort, dehydration, and malnutrition, while its protective benefits remain uncertain. We hypothesize that maintaining oral intake does not increase the risk of intubation or aspiration-related complications.",[273,36,274,275,276],"Respiratory Insufficiency","Dysphagia","Swallowing Disorder","Aspiration",[278,279,280,281,282,283],"acute respiratory failure","fasting","oral intake","aspiration","intubation","high-flow nasal oxygen","2026-02-13",{"date":286,"type":50},"2026-02-18",{"date":288,"type":50},"2025-02-05",{"date":290,"type":22},"2028-03",{"name":292,"class":99},"University Hospital, Tours",14,{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":108,"sex":17,"minAge":300,"maxAge":144,"enrollmentInfo":301,"targetDuration":4,"studyType":23,"phases":303,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":136},"100447289","immunomodulatory-effects-of-fasting-in-healthy-adults-100447289","NCT05104502","Immunomodulatory Effects of Fasting in Healthy Adults","Inclusion Criteria:\n\n* Age: 20-40 years, to constitute a young study population\n* Gender: male subjects, to control for gender differences\n* BMI: 19-27 kg\u002Fm2 to constitute a normal\u002Fhealthy weight population\n* Weight: 120 lbs or more\n* Fasting glucose: 70-100 mg\u002FdL, to ensure that fasting can be tolerated without inducing dangerously low levels of blood glucose\n* Subjects must be willing to undergo a period of 36 hours of water-only fasting\n* Subjects must be willing to collect samples of each bowel movement produced throughout the entire study period for microbiome analysis\n* Subjects must be willing to collect blood pricks for blood glucose levels using a Contour Next One Blood Glucose Testing Kit during the fasting stage of the study protocol.\n\nExclusion Criteria:\n\n* Current smoking\n* Anemia\n* Pregnancy or current breastfeeding\n* Chronic diseases including diabetes mellitus, thyroid disease, metabolic syndrome, cancer, or previous cardiovascular events\n* Gastrointestinal diseases including irritable bowel syndrome, Crohn's disease, ulcerative colitis, celiac disease\n* Consumption of \\>1 alcoholic drink\u002Fday\n* Extreme dietary or exercise patterns\n* Recent weight fluctuations (greater than 10% in the last six months)\n* Regular use of over-the-counter allergy or pain medications (\\>1\u002Fweek)\n* Taking prescription lipid medications (e.g. statins) or other supplements known to alter lipoprotein metabolism such as isoflavones\n* Use of hormonal birth control including oral contraception pills, hormonal IUDs or rings, or hormonal birth control patches","20 Years",{"count":302,"type":22},4,[70],"This is a clinical trial assessing the effects of fasting on the immune system in healthy adults. Immune profiling, gene expression profiling, and flow cytometry on peripheral blood mononuclear cells (PBMCs) will be performed and we hypothesize that a period of fasting will alter the immune system in healthy adults.",[36],"2025-11-25",{"date":308,"type":50},"2025-12-02",{"date":310,"type":50},"2022-03-25",{"date":312,"type":22},"2026-06",{"name":314,"class":99},"University of California, Davis",{"id":316,"slug":4,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":108,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":320,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":322,"conditions":323,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":136},"100609623","NCT07216989","Fastomics: Metabolic and Therapeutic Effects of Prolonged Fasting","Inclusion Criteria:\n\n* Ages of 18-65 years old\n* Not pregnant\n* No comorbid conditions\n* BMI of 18.5-29.9.\n* Has a smartphone\n\nExclusion Criteria:\n\n* Concern for active eating disorder per screening questionnaire\n* Self-reported eating disorder or history of eating disorder\n* History of hypoglycemia or contraindication for Prolonged Fasting\n* Weight \\\u003C120lbs\n* History of blood donation within the last 3 months.",{"count":321,"type":22},15,"This is an observational study investigating how the metabolic and cell marker changes in Prolonged Fasting in the serum may be used against a cell-based model of disease for therapeutic purposes.",[324,36],"Insulin Resistance","2025-10-13",{"date":327,"type":50},"2025-10-15",{"date":329,"type":50},"2025-08-05",{"date":331,"type":22},"2026-10-01",{"name":333,"class":99},"University of Minnesota",{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":108,"sex":17,"minAge":18,"maxAge":144,"enrollmentInfo":342,"targetDuration":4,"studyType":23,"phases":344,"briefSummary":345,"conditions":346,"keywords":347,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":350,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":136},"100526401","mechanisms-of-fasting-induced-reduction-in-energy-expenditure-100526401","NCT06134258","Mechanisms of Fasting Induced Reduction in Energy Expenditure","Mechanisms of Fasting Induced Reduction in Energy Expenditure - FIRE Trial","FIRE","Inclusion Criteria:\n\n* Age: 18 to 40 years\n* Body mass index 18.0 to 27.0 kg\u002Fm²\n* Exclusion Criteria:\n* Chronic conditions necessitating medical treatment (e.g., renal failure, hepatic dysfunction, cardiovascular disease, diabetes mellitus),\n* Known or suspected non-compliance, drug or alcohol abuse,\n* Inability to follow the procedures of the study\n* Participation in another study with investigational drug within the 30 days preceding and during the present study,\n* Previous enrolment into the current study,\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons,\n* Hypothyroidism or hyperthyroidism\n* Pregnant, breastfeeding and menopausal women",{"count":343,"type":22},40,[70],"Fasting reduces the energy consumption of the human body. The extent of this adaptation varies significantly between different individuals. The aim of this research project is to investigate how this adaptation of the metabolism is regulated by the body. For this purpose, we will first measure how the so-called basal metabolic rate of the body reacts to a short-term fasting of 24 h in a preliminary study. Those subjects with a particularly pronounced and those subjects with an only slightly pronounced reaction of the basal metabolic rate will be invited to the main study.\n\nHere, in random order (24 h fasting vs. 8 h fasting), the following is compared\n\n* how the basal metabolic rate of the body reacts to the reduced energy intake.\n* how the energy metabolism increases after a test meal\n* what role in particular the thyroid hormones play in this adaptation. In addition, a sample of the subcutaneous adipose tissue is taken in each case and it is examined how the regulation of metabolic processes at the cellular level.",[36],[348],"Thermogenesis","2025-05-26",{"date":351,"type":50},"2025-05-30",{"date":353,"type":50},"2023-11-15",{"date":355,"type":22},"2026-04-18",{"name":357,"class":99},"ETH Zurich",{"id":359,"slug":360,"hasResults":11,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":23,"phases":368,"briefSummary":369,"conditions":370,"keywords":372,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":387},"100505122","therapeutic-fasting-and-immune-aging-100505122","NCT05857241","Therapeutic Fasting and Immune Aging","Therapeutic Fasting and Immune Aging: A Pilot Study of Tolerance","JÛVENILE","Inclusion Criteria :\n\n* Patient affiliated or entitled to a social security scheme\n* Residing in a Long-Term Care Unit (LTCU) or a Facility for the Elderly Dependent (EHPAD)\n* A person deemed a priori, by the geriatrician member of the monitoring committee, to be capable of following the dietary recommendations required for the study.\n* A person deemed a priori, by the clinician in charge, to be able to follow the dietary recommendations required by the study.\n* Patient who has received informed information about the study and has co-signed a consent to participate in the study with the investigator.\n\nExclusion Criteria :\n\n* Inability and\u002For unwillingness to follow dietary recommendations and\u002For perform follow-up examinations required for the study\n* Iso-resource group 1 or 2 according to the AGGIR grid\n* BMI \\\u003C 18.5 kg\u002Fm2 or recent weight loss \\> 5% in 1 month or recent weight loss \\> 10% in 6 months from previous weight\n* Albuminemia \\\u003C 30g\u002Fl\n* All swallowing disorders requiring a specific diet.\n* Influenza vaccination received prior to inclusion\n* Episode of influenza or suspected influenza during the 2020-2021 season and prior to inclusion\n* Any acute medical or surgical event less than 2 weeks prior to inclusion\n* Presence of systemic inflammatory or autoimmune disease\n* Presence of an innate or acquired immune deficiency (including taking immunosuppressive treatment)\n* Presence of a chronic disease which, according to the physician, makes the follow-up of a \"fasting diet\" and\u002For the consumption of large amounts of liquids (cf. fasting diet modalities) risky (e.g. insulin-dependent or insulin-requiring diabetes, severe heart failure, severe kidney failure, active cancer, significant undernutrition...) or impossible (e.g. advanced neurodegenerative pathology).",{"count":367,"type":22},20,[70],"Immunosenescence is the age-related decline of the immune system, involving a state of chronic inflammation and a decrease in the diversity\u002Fadaptability of the lymphocyte repertoire. The consequences of immunosenescence are multiple, including increased susceptibility to infections and poorer vaccine responses.",[36,371],"Diet, Healthy",[373,374,375,376,377],"Fasting mimicking diet","Aged","immunology","immunosenescence","tolerance","2025-04-07",{"date":380,"type":50},"2025-04-08",{"date":382,"type":22},"2025-04",{"date":384,"type":22},"2026-03",{"name":386,"class":99},"Centre Hospitalier Universitaire de Saint Etienne",5,{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":108,"sex":17,"minAge":18,"maxAge":395,"enrollmentInfo":396,"targetDuration":4,"studyType":23,"phases":398,"briefSummary":399,"conditions":400,"keywords":404,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":136},"100583627","postprandial-metabolome-and-metabolic-flexibility-100583627","NCT06878781","Postprandial Metabolome and Metabolic Flexibility","Standardized Meals With Different Macronutrient Ratios on the Postprandial Metabolome and Metabolic Flexibility","Inclusion Criteria:\n\n* be over 18 years of age and under 30 years of age;\n* without active drug addictions: smoking, alcoholism, and\u002For drug addiction;\n* in female subjects: regular menstrual cycles;\n* give written consent for their inclusion in the study.\n\nExclusion Criteria:\n\n* subjects with any pathology that requires medication or special treatment, such as type 2 diabetes mellitus, high blood pressure, dyslipidemia, polycystic ovary syn-drome, autoimmune, thyroid, kidney, neurological diseases, and cancer;\n* pregnant or lactating women;\n* subjects with problems with chewing, salivation, and swallowing.\n\nElimination criteria:\n\n* subjects who only have samples (blood and calorimetry) from one study period (fasting or postprandial);\n* subjects who only have samples (blood and calorimetry) of a metabolic challenge;\n* subjects who have an infection at the scheduled appointment;\n* subjects who withdraw their informed consent","30 Years",{"count":397,"type":22},300,[70],"Metabolic flexibility is a process in which the body can switch energy substrates in different physiological states. This flexibility plays an important role in an individual's health because losing it increases the risk of obesity, metabolic syndrome, insulin resistance, and type 2 diabetes. Considering that humans spend most of their awakening hours in a postprandial (PP) state, an organism's metabolic flexibility (MF) to respond to a standardized meal's consumption would provide information on the individual's metabolic health. The PP response to glucose following an oral glucose tolerance test or consumption of a high-carbohydrate meal is well described; however, few studies assess the FM and PP metabolome using mixed meals with different macronutrients. The investigators address how metabolic flexibility and metabolome change after consuming standardized meals with different macronutrient ratios. Data collection includes clinical and diet information, indirect calorimetry, and capillary blood sampling during fasting and after consumption of standardized meals. Samples are collected weekly for one month. The data will determine the metabolic flexibility and metabolome after consuming standardized meals with different macronutrient ratios.",[36,401,402,30,403],"Postprandial Hyperglycemia","Lipid Metabolism Disorders","Insulin Sensitivity",[405,406,407],"metabolic flexibility","postprandial response","mixed meals","2025-03-10",{"date":410,"type":50},"2025-03-17",{"date":412,"type":50},"2024-01-08",{"date":414,"type":22},"2026-12-18",{"name":416,"class":417},"Instituto Nacional de Medicina Genomica","OTHER_GOV",{"id":419,"slug":420,"hasResults":11,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":108,"sex":17,"minAge":426,"maxAge":427,"enrollmentInfo":428,"targetDuration":4,"studyType":23,"phases":429,"briefSummary":430,"conditions":431,"keywords":434,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":136},"100572742","the-impact-of-a-48-hour-fast-with-or-without-exercise-on-immune-cell-metabolism-and-glycemic-control-in-healthy-active-adults-100572742","NCT06737224","The Impact of a 48-hour Fast with or Without Exercise on Immune Cell Metabolism and Glycemic Control in Healthy Active Adults","The Impact of a 48-hour Fast with or Without Exercise on Immune Cell Function, Bioenergetics, and Glycemic Control in Healthy Active Adults: a Randomized Crossover Trial","FASTEX","Inclusion Criteria:\n\n* Aged between 19 and 35 years.\n* Physically active (engaging in ≥150 minutes of weekly moderate to vigorous physical activity).\n\nExclusion Criteria:\n\n* History of cardiometabolic diseases or inflammatory diseases (e.g., chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, cardiovascular disease).\n* Individuals currently following a ketogenic diet, low-calorie diet, periodic fasting regimen, or consuming ketogenic supplements (e.g., exogenous ketone drinks).\n* Cigarette\u002Fvaping smoking.\n* Physical limitation that will impair the ability of the participant to perform exercise.\n* Individuals having a body mass index (BMI) over 30 kg\u002Fm2.\n* Cancer diagnosis in the past 5 years.\n* Taking anti-inflammatory drugs (e.g., ibuprofen, aspirin, naproxen).\n* Being unable to read or communicate in English.","19 Years","35 Years",{"count":321,"type":22},[70],"Many individuals engage in fasting for its purported health benefits but the effects of fasting on immune cell and whole body metabolism are not well understood in humans. Moreover, how exercising during a prolonged fast impacts immunometabolic outcomes is unclear. This study will determine how a 2 day fast - performed with or without daily exercise - impacts immune cell bioenergetics, immune cell function, and whole-body glycemic control in healthy active individuals.",[36,432,433],"Immune Function","Glucose Tolerance",[435,436,437],"Exercise","Immunometabolism","Glycemic control","2025-03-04",{"date":440,"type":50},"2025-03-07",{"date":442,"type":50},"2025-01-10",{"date":444,"type":22},"2025-08-01",{"name":446,"class":99},"University of British Columbia",{"id":448,"slug":449,"hasResults":11,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":108,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":454,"targetDuration":4,"studyType":23,"phases":456,"briefSummary":457,"conditions":458,"keywords":459,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":464,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":136},"100575970","fasting-effects-on-metabolism-and-immunity-study-in-human-100575970","NCT06779201","Fasting Effects on Metabolism and Immunity Study in Human","Study on the Effect and Mechanism of Fasting on Human Metabolism and Immunity","Inclusion Criteria:\n\n1. Age 18-65 years old, gender is not limited;\n2. BMI≥18.5;\n3. Can tolerate a certain degree of hunger;\n4. Can voluntarily sign written informed consent.\n\nExclusion Criteria:\n\n1. Women planning pregnancy, pregnancy and breastfeeding;\n2. Previous liver disease, chronic kidney disease, heart disease and cerebrovascular disease;\n3. Suffering from acute infectious diseases or chronic wasting diseases;\n4. Have used antibiotic drugs in the past 3 months, and have used prebiotic or probiotic supplements or products in the past month;\n5. Participate in other clinical investigators within 3 months before enrollment in this study.",{"count":455,"type":22},30,[70],"This study aims to investigate the effects of 1-week fasting but not prohibiting water drink on human immune function, metabolic indicators, and brain function in human, and to explore the underlying mechanisms of these changes from a multi-omics perspective and\u002For other ways.",[36],[36,460,461,462,463],"Metabolism","Immunity","Brain function","Intestinal flora","2025-01-19",{"date":466,"type":50},"2025-01-22",{"date":468,"type":50},"2024-09-01",{"date":470,"type":22},"2027-12-31",{"name":472,"class":99},"Xuanwu Hospital, Beijing",{"id":474,"slug":475,"hasResults":11,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":108,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":480,"targetDuration":4,"studyType":23,"phases":482,"briefSummary":483,"conditions":484,"keywords":4,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":136},"100556258","phase-1-bioequivalence-study-of-sulfadoxinepyrimethamine-50025-mg-dispersible-tablet-100556258","NCT06522763","Bioequivalence Study of Sulfadoxine\u002FPyrimethamine 500\u002F25 mg Dispersible Tablet","Comparative Randomized, Single Dose, Two-Arm, Parallel Open Label Study to Determine the Bioequivalence of Sulfadoxine\u002FPyrimethamine 500\u002F25 mg Dispersible Tablet After an Oral Administration to Healthy Adults Under Fasting Conditions","Inclusion Criteria:\n\n1. Healthy subjects male or female (childbearing potential or surgically sterile female (confirmed by medical\u002Foperative report or if medical\u002Foperative report is not available by ultrasound test)), age 18 to 50 years, inclusive, for post-menopausal female aged between 45 and 65 years inclusive.\n2. Body Mass Index (BMI) range8 is within 18.5 - 30.0 Kg\u002Fm2.\n3. Subject does not have a known allergy to the drug under investigation or any of its ingredients or any other related drugs.\n4. Medical history and physical examination within medically acceptable criteria.\n5. Subjects having QTc value less than 450 msec for male or less than 440 msec for female at the time of screening.\n6. Negative pregnancy test or post-menopausal (ie, at least 1 year without menses and without an alternative medical condition prior to the Screening visit, confirmed by FSH test) if female.\n7. Laboratory investigations tests within laboratory reference ranges found in Annex I (ALP and creatinine are accepted if below the reference range after being evaluated by the physician as clinically not significant).\n8. Subject is capable of consent.\n9. Female subjects of childbearing potential and agrees to use total abstinence or an acceptable contraceptive method of the following: - Systemic contraceptives (birth control pills, injectable\u002F implantable\u002F insertable hormonal birth control products, transdermal patch) - Intrauterine device - Condom with intravaginal spermicide\n\nExclusion Criteria:\n\n1. Medical demographics performed not longer than two weeks before the initiation of the clinical study with significant deviations from the normal ranges\n2. Presence of any clinically significant results from laboratory tests found in Annex I, however, ALP and creatinine will be accepted if below reference range after being evaluated by the physician as clinically not significant. Laboratory tests are performed not longer than two weeks before the initiation of the clinical study.\n3. History of drug or alcohol abuse.\n4. Subject is a heavy smoker (more than 10 cigarettes per day).\n5. Subject does not agree to not taking any prescription or non-prescription drugs within at least two weeks before study drug administration and until donating the last sample of the study.\n6. Subject does not agree to not taking any vitamins taken for nutritional purposes within at least two days before study drug administration and until donating the last sample of the study.\n7. Subject is on a special diet (for example subject is vegetarian).\n8. Subject consumes large quantities of alcohol or beverages containing methylxanthines e.g. caffeine (coffee, tea, cola, energy drinks, chocolate etc.).\n9. Subject does not agree to not consuming any beverages or food containing alcohol at least 48 hours prior to study drug administration until donating the last sample of the study.\n10. Subject does not agree to not consuming any beverages or food containing methylxanthines e.g. caffeine (coffee, tea, cola, energy drinks, chocolate etc.) at least 24 hours prior to the study drug administration until the end of confinement.\n11. Subject does not agree to not consuming any beverages or food containing grapefruit at least 7 days prior to study drug administration until donating the last sample of the study.\n12. Subject has a history of severe diseases, which have direct impact on the study.\n13. Participation in a bioequivalence study or in a clinical study within the last 90 days before study drug.",{"count":481,"type":22},46,[199],"The primary objective of this study is to assess the bioequivalence between the test product and the reference product based on Cmax and AUC0-\\>72 for sulfadoxine and pyrimethamine in healthy adults under fasting conditions. The secondary objectives of present study are to describe the Tmax and assess the safety and tolerability profile of both test and reference products.",[36],"2024-07-25",{"date":487,"type":50},"2024-07-26",{"date":489,"type":22},"2024-07",{"date":491,"type":22},"2024-09",{"name":493,"class":57},"Swiss Pharma Nigeria Limited",{"id":495,"slug":496,"hasResults":11,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":500,"eligibilityCriteria":501,"healthyVolunteers":108,"sex":17,"minAge":18,"maxAge":502,"enrollmentInfo":503,"targetDuration":505,"studyType":112,"phases":4,"briefSummary":506,"conditions":507,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":531,"locationsCount":136},"100498046","safe-brain-initiative-operationalizing-precision-anaesthesia-100498046","NCT05765162","Safe Brain Initiative, Operationalizing Precision Anaesthesia","Safe Brain Initiative - Dedicated to Advancing Anaesthesia and Perioperative Personalised Care Towards Precision Anaesthesia Care. A Continuous Quality Improvement Initiative.","SBI","Inclusion Criteria:\n\n• All patients from age ≥18\n\nExclusion Criteria:\n\n• All patients from age \\\u003C18","100 Years",{"count":504,"type":22},15000,"5 Years","Perioperatively, patients experience an unnecessarily high level of side effects associated with their treatment. These side effects include nausea, severe pain, anxiety, and stress. Moreover, many patients develop postoperative delirium (POD) and neurocognitive dysfunctions, often resulting in long-term cognitive impairment, decreased quality of life, and increased mortality. However, physicians, nurses and their institutions do not receive structured feedback regarding these aspects of each patient's well-being. They may therefore be unable to engage in the essential cause-and-effect learning necessary to evaluate and consecutively reduce such side effects.\n\nEffective guidelines conform prevention is the proven key to shielding our patients from adverse Outcomes. The Safe Brain Initiative's high-quality routine data-for-action is a sword and accelerator for moving towards patient-centred, precision care. Thus, establishing a foundation for value-based and patient-centred healthcare development.\n\nHowever, a turnkey real-world solution is challenging to develop and implement and requires substantial resources. As a result, such solutions are usually beyond the scope of a single institution. The SBI platform provides high-quality, real-world data to bridge this gap. It allows monitoring and in-depth analysis of cause and effect in the day-to-day routine of individuals, departments, and institutions.\n\nThe SBI's approach is continuously improved and updated. An organization called the SBI Global Society oversees the quality and precision of science through experts in the field. At SBI Hospitals and Flagship centres, Masterclasses are conducted and can be attended alongside clinical immersions.\n\nSBI Solutions manages, develops, and provides technical and service support for the Safe Brain Initiative. Its service guarantees the professional and GDPR conform management of data handling and storage as well as the user-friendly functionality of the SBI-Dashboard solutions.",[508,509,510,511,512,513,514,515,516,517,518,519,520,521,36,522,523],"Neurocognitive Disorders","Post Operative Delirium","Pain","Nausea","Vomiting","Wellbeing","Shivering","Anxiety","Stress","Agitation,Psychomotor","Sedation Complication","Thirst","Satisfaction, Patient","Temperature Change, Body","Sore-throat","Hearing and Vision Loss","2024-06-05",{"date":526,"type":50},"2024-06-07",{"date":528,"type":50},"2021-12-01",{"date":530,"type":22},"2026-01-01",{"name":532,"class":99},"University of Southern Denmark",{"id":534,"slug":535,"hasResults":11,"nctId":536,"briefTitle":537,"officialTitle":538,"acronym":4,"eligibilityCriteria":539,"healthyVolunteers":11,"sex":17,"minAge":540,"maxAge":502,"enrollmentInfo":541,"targetDuration":4,"studyType":23,"phases":542,"briefSummary":543,"conditions":544,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":553,"locationsCount":136},"100519461","effectiveness-of-focused-tele-education-in-reducing-diabetes-complications-during-ramadan-100519461","NCT06043843","Effectiveness of Focused Tele-education in Reducing Diabetes Complications During Ramadan","Effectiveness of a Ramadan-focused Structured Diabetes Tele-education in Reducing Diabetes Complications During Ramadan Fasting in South East Asia","Inclusion Criteria:\n\n* Adults with diabetes planning to fast in Ramadan,\n\n  1. Adults with type 2 diabetes aged at least 21 years old,\n  2. Able to fast at least 15 days in Ramadan based on experience of fasting in previous year's Ramadan,\n  3. Underlying type 2 diabetes treated with basal insulin and one or more doses of prandial insulin, or at least twice-daily premixed insulin\n  4. Performed laboratory tests as per standard care - glycated haemoglobin (HbA1c), serum Low Density Lipoprotein- cholesterol, serum triglycerides, serum High Density Lipoprotein- cholesterol, serum Total cholesterol and serum creatinine\n  5. Ability to give informed consent,\n  6. Ability to perform self-monitoring blood glucose\n  7. Have had diabetes-related clinic visits or hospitalization in the past 10 months.\n  8. Have the capacity for video conferencing (internet connection with mobile phone or computer)\n\nExclusion Criteria:\n\n1. Severe diabetes complications including end-stage renal failure\n2. Severe hypoglycemia and hyperglycemic crises within the last 3 months\n3. Advanced comorbidities negating the ability to fast\n4. Pregnancy\n5. Patients on oral medications alone or oral medications plus basal insulin alone\n6. Patients on sulfonylureas","21 Years",{"count":397,"type":22},[70],"Introduction Diabetes is a global emergency with detrimental clinical and financial consequences. Poorly managed diabetes leads to a myriad of serious complications, especially cardiovascular and infectious complications, with consequent increased cost and mortality rate. For Muslims in particular, the annual fasting month of Ramadan is one such period when diabetes control is essential. Adequate adjustments in diabetes management need to be made in line with the allowed mealtimes to avoid the risk of diabetes complications during Ramadan.\n\nObjective Investigators aim to investigate the effectiveness of Ramadan-focused structured diabetes tele-education to reduce diabetes complications during Ramadan fasting for Muslims with diabetes in South East Asia.\n\nMethodology In a parallel group randomized controlled trial, investigators aim to recruit 300 adults with diabetes who are able to fast at least 15 days in Ramadan. You will be randomized to the intervention group comprising of a Ramadan-focused structured diabetes tele-education and control group receiving standard care. You will be reviewed again after Ramadan. The primary outcome is the incidence of hypoglycemia in Ramadan. The secondary outcomes are incidence of other diabetes complications in Ramadan episodes including hyperglycemia, episodes of acute infections, attendances in clinic and emergency department, hospital admissions, and compliance to recommendations for diabetes management during Ramadan.\n\nClinical Significance The study enables investigators to evaluate Ramadan-focused structured diabetes tele-education to reduce the risk of diabetes complications for a large population during the fasting month.",[545,36,546],"Diabetes Mellitus","Diabetes Complications","2023-09-12",{"date":549,"type":50},"2023-09-21",{"date":551,"type":50},"2021-02-16",{"date":312,"type":22},{"name":554,"class":99},"Sengkang General Hospital"]